Andrew J Mirelman1, Sarah Blythe Ballard2, Mayuko Saito3, Margaret N Kosek4, Robert H Gilman5. 1. Centre for Health Economics, University of York, Heslington, United Kingdom. 2. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: sballar3@jhu.edu. 3. Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan; Asociación Benéfica PRISMA, Lima, Peru. 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima, Peru.
Abstract
BACKGROUND: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. METHODS: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. RESULTS: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. CONCLUSIONS: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher. Published by Elsevier Ltd.
BACKGROUND: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. METHODS: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. RESULTS: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. CONCLUSIONS: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher. Published by Elsevier Ltd.
Authors: R I Cama; U D Parashar; D N Taylor; T Hickey; D Figueroa; Y R Ortega; S Romero; J Perez; C R Sterling; J R Gentsch; R H Gilman; R I Glass Journal: J Infect Dis Date: 1999-05 Impact factor: 5.226
Authors: Robert L Atmar; David I Bernstein; Clayton D Harro; Mohamed S Al-Ibrahim; Wilbur H Chen; Jennifer Ferreira; Mary K Estes; David Y Graham; Antone R Opekun; Charles Richardson; Paul M Mendelman Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245
Authors: Umesh D Parashar; Jin-Fen Li; Rosa Cama; Mark DeZalia; Stephan S Monroe; David N Taylor; Dante Figueroa; Robert H Gilman; Roger I Glass Journal: J Infect Dis Date: 2004-08-02 Impact factor: 5.226
Authors: Andrew D Clark; Damian G Walker; N Rocio Mosqueira; Mary E Penny; Claudio F Lanata; Julia Fox-Rushby; Colin F B Sanderson Journal: J Infect Dis Date: 2009-11-01 Impact factor: 5.226
Authors: Christa L Fischer Walker; Jamie Perin; Martin J Aryee; Cynthia Boschi-Pinto; Robert E Black Journal: BMC Public Health Date: 2012-03-21 Impact factor: 3.295
Authors: Umesh D Parashar; Erik G Hummelman; Joseph S Bresee; Mark A Miller; Roger I Glass Journal: Emerg Infect Dis Date: 2003-05 Impact factor: 6.883
Authors: Bach Xuan Tran; Victoria L Boggiano; Long Hoang Nguyen; Carl A Latkin; Huong Lan Thi Nguyen; Tung Thanh Tran; Huong Thi Le; Thuc Thi Minh Vu; Cyrus Sh Ho; Roger Cm Ho Journal: Patient Prefer Adherence Date: 2018-09-06 Impact factor: 2.711
Authors: Sarah-Blythe Ballard; Aaron Tallant; Rosio G Guerra; Dawn Quigley; Regan Stiegmann; Andrew J Mirelman; Mark S Riddle; Robert H Gilman Journal: Vaccine Date: 2020-02-01 Impact factor: 4.169